Goldman Sachs initiates BioMarin stock coverage at neutral on competitive concerns

Goldman Sachs initiated BioMarin (BMRN) at Neutral with a $69 price target, above the current $54.06 share price, but cited limited near-term catalysts and increasing competition for Voxzogo. The firm modeled a 6% annual decline in achondroplasia sales from 2027 to 2035 and highlighted competitive threats from BridgeBio, Ascendis, and Tyra, partially offset by mid-single-to-high growth pipeline potential including ENPP1 deficiency data with $69 million peak sales. BioMarin also reported Q1 2026 EPS of $0.76 versus $0.74 expected and revenue of $766 million versus $755.94 million, though shares fell in after-hours trading.

Analysis

The market is still treating BMRN as a mature single-asset story, but the more important setup is a slow-motion revenue handoff: management now has a visible clock on Voxzogo deceleration, while the acquired rare-disease assets only partially offset it and likely underwhelm on near-term multiple expansion. That creates a mismatch between headline valuation support and forward earnings power; in biotech, that usually means the stock can sit cheap for a long time before re-rating.

The real second-order risk is competitive optionality. An oral achondroplasia therapy with broader convenience would not just pressure new starts; it could also compress treatment duration and pricing power, forcing a faster-than-modeled decline in the core franchise. If that competitive read is right, the market is likely underestimating how quickly physician switching can happen once a credible alternative approaches launch, especially in a pediatric setting where adherence and administration burden matter.

On the flip side, consensus may be too pessimistic on the pipeline as a zero-sum offset. ENPP1 and next-gen growth disorder data are the kind of binary catalysts that can reframe the narrative over 6-18 months, and the stock being near cycle lows means even modest clinical wins could drive a sharp squeeze higher. The issue is timing: absent a clean data beat, the equity likely trades as a value trap until investors get more clarity on synergy capture and post-acquisition profitability.

For GS, the call is mildly positive for stock selection but more important as a signal that sell-side patience is thinning. The named competitors face different risks: BBIO carries the biggest commercial upside if oral convenience wins, ASND looks more like a durability/efficacy debate, and TYRA remains a longer-dated sentiment arbiter than a near-term earnings driver. That argues for expressing the view via relative trades rather than outright direction.

Key Decisions for Investors

• Short BMRN vs long IBB for 3-6 months: thesis is idiosyncratic commercial decay plus limited near-term catalysts; target 10-15% relative underperformance, stop if ENPP1 data is clearly positive.
• Buy BBIO on pullbacks, but only as a 12-24 month optionality trade: the market is underpricing oral-convenience disruption; risk/reward improves into clinical de-risking windows rather than ahead of them.
• Use BMRN calls only as a catalyst trade into ENPP1 data in Q2: 3-6 month upside can be sharp if the readout expands the pipeline narrative, but keep downside capped because the stock still trades like a value name.
• Short-dated put spread on BMRN into the next earnings call: limited downside if results merely meet, but a weak synergy/profitability update could reopen the multiple compression; structure for a 2-1 or better payoff.
• Relative long ASND vs short TYRA is the cleaner competitive pair: ASND has a more credible near-term commercial path, while TYRA is better treated as a high-beta sympathy name with less immediate fundamental torque.